{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T15:14:38Z","timestamp":1774451678101,"version":"3.50.1"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100007219","name":"Natural Science Foundation of Shanghai","doi-asserted-by":"publisher","award":["19ZR1410400"],"award-info":[{"award-number":["19ZR1410400"]}],"id":[{"id":"10.13039\/100007219","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.lungcan.2022.07.011","type":"journal-article","created":{"date-parts":[[2022,7,19]],"date-time":"2022-07-19T02:10:23Z","timestamp":1658196623000},"page":"18-25","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Genetic correlation of crizotinib efficacy and resistance in ALK- rearranged non-small-cell lung cancer"],"prefix":"10.1016","volume":"171","author":[{"given":"Chang","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cuicui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiatao","family":"Liao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiani C.","family":"Yin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xianghua","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinmin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Si","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huijie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhihuang","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Shao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jialei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"23","key":"10.1016\/j.lungcan.2022.07.011_b0005","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1056\/NEJMoa1408440","article-title":"First-line crizotinib versus chemotherapy in ALK-positive lung cancer","volume":"371","author":"Solomon","year":"2014","journal-title":"New Engl. J. Med."},{"issue":"25","key":"10.1016\/j.lungcan.2022.07.011_b0010","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1056\/NEJMoa1214886","article-title":"Crizotinib versus chemotherapy in advanced ALK-positive lung cancer","volume":"368","author":"Shaw","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.lungcan.2022.07.011_b0015","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.21037\/tlcr-21-160","article-title":"Concomitant mutation status of ALK-rearranged non-small cell lung cancers and its prognostic impact on patients treated with crizotinib","volume":"10","author":"Li","year":"2021","journal-title":"Transl. Lung Cancer Res."},{"key":"10.1016\/j.lungcan.2022.07.011_b0020","unstructured":"J. No\u00e9, A. Lovejoy, S.I. Ou, S.J. Yaung, W. Bordogna, D.M. Klass, C.A. Cummings, A.T. Shaw, ALK Mutation Status Before and After Alectinib Treatment in Locally Advanced or Metastatic ALK-Positive NSCLC: Pooled Analysis of Two Prospective Trials, (1556-1380 (Electronic))."},{"key":"10.1016\/j.lungcan.2022.07.011_b0025","unstructured":"J.F. Gainor, L. Dardaei, S. Yoda, L. Friboulet, I. Leshchiner, R. Katayama, I. Dagogo-Jack, S. Gadgeel, K. Schultz, M. Singh, E. Chin, M. Parks, D. Lee, R.H. DiCecca, E. Lockerman, T. Huynh, J. Logan, L.L. Ritterhouse, L.P. Le, A. Muniappan, S. Digumarthy, C. Channick, C. Keyes, G. Getz, D. Dias-Santagata, R.S. Heist, J. Lennerz, L.V. Sequist, C.H. Benes, A.J. Iafrate, M. Mino-Kenudson, J.A. Engelman, A.T. Shaw, Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer, (2159-8290 (Electronic))."},{"issue":"9","key":"10.1016\/j.lungcan.2022.07.011_b0030","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1111\/1759-7714.12791","article-title":"Heterogeneous responses and resistant mechanisms to crizotinib in ALK-positive advanced non-small cell lung cancer","volume":"9","author":"Kang","year":"2018","journal-title":"Thorac. Cancer"},{"issue":"8","key":"10.1016\/j.lungcan.2022.07.011_b0035","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1200\/JCO.2012.44.5353","article-title":"ALK in lung cancer: past, present, and future","volume":"31","author":"Shaw","year":"2013","journal-title":"J. Clin. Oncol."},{"issue":"16","key":"10.1016\/j.lungcan.2022.07.011_b0040","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1002\/cncr.28597","article-title":"ALK-positive non-small cell lung cancer: mechanisms of resistance and emerging treatment options","volume":"120","author":"Steuer","year":"2014","journal-title":"Cancer"},{"issue":"12","key":"10.1016\/j.lungcan.2022.07.011_b0045","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1200\/JCO.2017.76.2294","article-title":"Impact of EML4-ALK variant on resistance mechanisms and clinical outcomes in ALK-positive lung cancer","volume":"36","author":"Lin","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.lungcan.2022.07.011_b0050","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/j.jtho.2020.02.007","article-title":"Detection of nonreciprocal\/reciprocal ALK translocation as poor predictive marker in patients with first-line crizotinib-treated ALK-rearranged NSCLC","volume":"15","author":"Zhang","year":"2020","journal-title":"J. Thorac. Oncol."},{"issue":"10026","key":"10.1016\/j.lungcan.2022.07.011_b0055","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1016\/S0140-6736(15)01125-3","article-title":"Large-scale screening for somatic mutations in lung cancer","volume":"387","author":"Rosell","year":"2016","journal-title":"Lancet (London, England)"},{"issue":"4","key":"10.1016\/j.lungcan.2022.07.011_b0060","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1093\/annonc\/mdw693","article-title":"Differential protein stability and clinical responses of EML4-ALK fusion variants to various ALK inhibitors in advanced ALK-rearranged non-small cell lung cancer","volume":"28","author":"Woo","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2022.07.011_b0065","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.596937","article-title":"Complex ALK fusions are associated with better prognosis in advanced non-small cell lung cancer","volume":"10","author":"Kang","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.lungcan.2022.07.011_b0070","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.lungcan.2018.01.026","article-title":"Response to crizotinib in advanced ALK-rearranged non-small cell lung cancers with different ALK-fusion variants","volume":"118","author":"Li","year":"2018","journal-title":"Lung Cancer"},{"issue":"28","key":"10.1016\/j.lungcan.2022.07.011_b0075","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1200\/JCO.2015.65.8732","article-title":"Differential crizotinib response duration among ALK fusion variants in ALK-positive non-small-cell lung cancer","volume":"34","author":"Yoshida","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.lungcan.2022.07.011_b0080","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s11523-019-00631-x","article-title":"Distribution of ALK fusion variants and correlation with clinical outcomes in chinese patients with non-small cell lung cancer treated with crizotinib","volume":"14","author":"Su","year":"2019","journal-title":"Target Oncol."},{"key":"10.1016\/j.lungcan.2022.07.011_b0085","first-page":"126","volume":"158","author":"Zhang","year":"2021","journal-title":"Going beneath the tip of the iceberg. Identifying and understanding EML4-ALK variants and TP53 mutations to optimize treatment of ALK fusion positive (ALK+) NSCLC, Lung cancer"},{"key":"10.1016\/j.lungcan.2022.07.011_b0090","doi-asserted-by":"crossref","unstructured":"Z. Yang, N. Yang, Q. Ou, Y. Xiang, T. Jiang, X. Wu, H. Bao, X. Tong, X. Wang, Y.W. Shao, Y. Liu, Y. Wang, C. Zhou, Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non-Small Cell Lung Cancer Patients, Clin Cancer Res 24(13) (2018) 3097-3107.","DOI":"10.1158\/1078-0432.CCR-17-2310"},{"key":"10.1016\/j.lungcan.2022.07.011_b0095","doi-asserted-by":"crossref","unstructured":"W. Fang, Y. Ma, J.C. Yin, S. Hong, H. Zhou, A. Wang, F. Wang, H. Bao, X. Wu, Y. Yang, Y. Huang, H. Zhao, Y.W. Shao, L. Zhang, Comprehensive Genomic Profiling Identifies Novel Genetic Predictors of Response to Anti-PD-(L)1 Therapies in Non-Small Cell Lung Cancer, Clin Cancer Res 25(16) (2019) 5015-5026.","DOI":"10.1158\/1078-0432.CCR-19-0585"},{"issue":"1","key":"10.1016\/j.lungcan.2022.07.011_b0100","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/s41598-017-00520-1","article-title":"Circulating tumor DNA mutation profiling by targeted next generation sequencing provides guidance for personalized treatments in multiple cancer types","volume":"7","author":"Shu","year":"2017","journal-title":"Sci. Rep."},{"issue":"19","key":"10.1016\/j.lungcan.2022.07.011_b0105","doi-asserted-by":"crossref","first-page":"5532","DOI":"10.7150\/thno.34070","article-title":"Tumor-derived DNA from pleural effusion supernatant as a promising alternative to tumor tissue in genomic profiling of advanced lung cancer","volume":"9","author":"Tong","year":"2019","journal-title":"Theranostics"},{"issue":"20","key":"10.1016\/j.lungcan.2022.07.011_b0110","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1097\/CM9.0000000000001097","article-title":"Circulating tumor DNA in lung cancer: real-time monitoring of disease evolution and treatment response","volume":"133","author":"Li","year":"2020","journal-title":"Chin. Med. J. (Engl.)"},{"issue":"15","key":"10.1016\/j.lungcan.2022.07.011_b0115","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1093\/bioinformatics\/btu170","article-title":"Trimmomatic: a flexible trimmer for Illumina sequence data","volume":"30","author":"Bolger","year":"2014","journal-title":"Bioinformatics"},{"issue":"14","key":"10.1016\/j.lungcan.2022.07.011_b0120","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1093\/bioinformatics\/btp324","article-title":"Fast and accurate short read alignment with Burrows-Wheeler transform","volume":"25","author":"Li","year":"2009","journal-title":"Bioinformatics"},{"issue":"9","key":"10.1016\/j.lungcan.2022.07.011_b0125","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1101\/gr.107524.110","article-title":"The genome analysis toolkit: a mapreduce framework for analyzing next-generation DNA sequencing data","volume":"20","author":"McKenna","year":"2010","journal-title":"Genome Res."},{"issue":"3","key":"10.1016\/j.lungcan.2022.07.011_b0130","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1101\/gr.129684.111","article-title":"VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing","volume":"22","author":"Koboldt","year":"2012","journal-title":"Genome Res."},{"issue":"4","key":"10.1016\/j.lungcan.2022.07.011_b0135","doi-asserted-by":"crossref","first-page":"e1004873","DOI":"10.1371\/journal.pcbi.1004873","article-title":"CNVkit: genome-wide copy number detection and visualization from targeted DNA sequencing","volume":"12","author":"Talevich","year":"2016","journal-title":"PLoS Comput. Biol."},{"issue":"7","key":"10.1016\/j.lungcan.2022.07.011_b0140","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1093\/annonc\/mdx185","article-title":"The clinical impact of an EML4-ALK variant on survival following crizotinib treatment in patients with advanced ALK-rearranged non-small-cell lung cancer","volume":"28","author":"Seo","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2022.07.011_b0145","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.lungcan.2018.11.024","article-title":"Concomitant resistance mechanisms to multiple tyrosine kinase inhibitors in ALK-positive non-small cell lung cancer","volume":"127","author":"Yu","year":"2019","journal-title":"Lung Cancer"},{"issue":"7","key":"10.1016\/j.lungcan.2022.07.011_b0150","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/j.jtho.2019.03.007","article-title":"Updated efficacy and safety data and impact of the EML4-ALK fusion variant on the efficacy of alectinib in untreated ALK-positive advanced non-small cell lung cancer in the global phase III ALEX study","volume":"14","author":"Camidge","year":"2019","journal-title":"J. Thorac. Oncol."},{"issue":"12","key":"10.1016\/j.lungcan.2022.07.011_b0155","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1016\/j.jtho.2021.07.035","article-title":"Brigatinib versus crizotinib in ALK inhibitor-naive advanced ALK-positive NSCLC: final results of phase 3 ALTA-1L trial","volume":"16","author":"Camidge","year":"2021","journal-title":"J. Thorac. Oncol."},{"issue":"10","key":"10.1016\/j.lungcan.2022.07.011_b0160","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1093\/annonc\/mdy333","article-title":"Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer","volume":"29","author":"Kron","year":"2018","journal-title":"Ann. Oncol."},{"issue":"4","key":"10.1016\/j.lungcan.2022.07.011_b0165","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1002\/cam4.2043","article-title":"Concomitant TP53 mutations with response to crizotinib treatment in patients with ALK-rearranged non-small-cell lung cancer","volume":"8","author":"Song","year":"2019","journal-title":"Cancer Med."},{"key":"10.1016\/j.lungcan.2022.07.011_b0170","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.2147\/DDDT.S196189","article-title":"Frequency, clinical features and differential response to therapy of concurrent ALK\/EGFR alterations in Chinese lung cancer patients","volume":"13","author":"Liu","year":"2019","journal-title":"Drug Des. Devel. Ther."},{"issue":"2","key":"10.1016\/j.lungcan.2022.07.011_b0175","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1158\/2159-8290.CD-16-1123","article-title":"Targeting ALK: precision medicine takes on drug resistance","volume":"7","author":"Lin","year":"2017","journal-title":"Cancer Discov."},{"issue":"7","key":"10.1016\/j.lungcan.2022.07.011_b0180","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.trecan.2016.05.010","article-title":"Resisting resistance: targeted therapies in lung cancer","volume":"2","author":"Lin","year":"2016","journal-title":"Trends Cancer"},{"key":"10.1016\/j.lungcan.2022.07.011_b0185","doi-asserted-by":"crossref","unstructured":"L. Friboulet, N. Li, R. Katayama, C.C. Lee, J.F. Gainor, A.S. Crystal, P.Y. Michellys, M.M. Awad, N. Yanagitani, S. Kim, A.C. Pferdekamper, J. Li, S. Kasibhatla, F. Sun, X. Sun, S. Hua, P. McNamara, S. Mahmood, E.L. Lockerman, N. Fujita, M. Nishio, J.L. Harris, A.T. Shaw, J.A. Engelman, The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer, Cancer Discov 4(6) (2014) 662-673.","DOI":"10.1158\/2159-8290.CD-13-0846"},{"issue":"8","key":"10.1016\/j.lungcan.2022.07.011_b0190","doi-asserted-by":"crossref","first-page":"e24917","DOI":"10.1097\/MD.0000000000024917","article-title":"BRAF V600E mutation as a novel mechanism of acquired resistance to ALK inhibition in ALK-rearranged lung adenocarcinoma: a case report","volume":"100","author":"Sui","year":"2021","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"10.1016\/j.lungcan.2022.07.011_b0195","doi-asserted-by":"crossref","first-page":"124","DOI":"10.3390\/cancers11010124","article-title":"Detection of TP53 Mutations in Tissue or Liquid Rebiopsies at Progression Identifies ALK+ Lung Cancer Patients with Poor Survival","volume":"11","author":"Christopoulos","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.lungcan.2022.07.011_b0200","doi-asserted-by":"crossref","unstructured":"D. Jia, A. Augert, D.W. Kim, E. Eastwood, N. Wu, A.H. Ibrahim, K.B. Kim, C.T. Dunn, S.P.S. Pillai, A.F. Gazdar, H. Bolouri, K.S. Park, D. MacPherson, Crebbp Loss Drives Small Cell Lung Cancer and Increases Sensitivity to HDAC Inhibition, Cancer Discov 8(11) (2018) 1422-1437.","DOI":"10.1158\/2159-8290.CD-18-0385"},{"key":"10.1016\/j.lungcan.2022.07.011_b0205","article-title":"EGFR-mutated squamous cell lung cancer and its association with outcomes","volume":"11","author":"Jin","year":"2021","journal-title":"Front. Oncol."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500222005517?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500222005517?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T12:59:50Z","timestamp":1759237190000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500222005517"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":41,"alternative-id":["S0169500222005517"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2022.07.011","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Genetic correlation of crizotinib efficacy and resistance in ALK- rearranged non-small-cell lung cancer","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2022.07.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}